Clinical Trials on Stage IVA Primary Peritoneal Cancer AJCC v8

Total 3703 results

Mayo Clinic
National Cancer Institute (NCI)

Completed

TAS-102 in Treating Advanced Biliary Tract Cancers

Cholangiocarcinoma | Stage III Gallbladder Cancer AJCC v7 | Stage IIIA Gallbladder Cancer AJCC v7 | Stage IIIB Gallbladder Cancer AJCC v7 | Stage IV Gallbladder Cancer AJCC v7 | Stage IVA Gallbladder Cancer AJCC v7 | Stage IVB Gallbladder Cancer AJCC v7

United States
Mayo Clinic

Recruiting

Relationship Between Alterations in the GI Microbiome and GI Inflammation on Symptom Burden in Women With Breast Cancer Receiving Chemotherapy

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colon Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal Carcinoma

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Lung Small Cell Carcinoma | Recurrent Lung Small Cell Carcinoma

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Lung Adenocarcinoma | Recurrent Lung Non-Small Cell Carcinoma | Recurrent Lung Adenocarcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8

United States, Canada
Mayo Clinic

Not yet recruiting

Evaluating Changes in Quality of Life After Near Margin-less Adaptive Radiation Therapy Compared to Standard Stereotactic Ablative Body Radiotherapy in Localized Prostate Cancer

Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Localized Prostate Adenocarcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

An Investigational Scan (68Ga-FAPI-46 PET/CT) for the Imaging of Cancer-Associated Fibroblasts in Patients With Localized Pancreatic Ductal Adenocarcinoma

Stage 0 Pancreatic Cancer AJCC v8 | Stage I Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Resectable Pancreatic Ductal Adenocarcinoma | Localized Pancreatic Adenocarcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Malignant Solid Neoplasm | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Breast Adenocarcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma... and other conditions

United States
M.D. Anderson Cancer Center
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation

Stage III Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Locally Advanced Lung Non-Small Cell Carcinoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Rectal Adenocarcinoma | Colon Adenocarcinoma | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...

United States
Emory University
National Cancer Institute (NCI)

Withdrawn

Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Resectable Intrahepatic Cholangiocarcinoma | Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8 | Stage I Intrahepatic Cholangiocarcinoma AJCC v8

United States
University of Kansas Medical Center
National Cancer Institute (NCI)

Recruiting

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Cholangiocarcinoma | Locally Advanced Cholangiocarcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent Cholangiocarcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic... and other conditions

United States
Providence Health & Services

Recruiting

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

BRAF V600E Mutation Present | Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8 | Refractory Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | BRAF NP_004324.2:p.V600M | Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8 | Stage IVB Differentiated Thyroid Gland Carcinoma...

United States
City of Hope Medical Center
National Cancer Institute (NCI); Imugene Limited

Active, not recruiting

CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
Mayo Clinic

Recruiting

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

Biochemically Recurrent Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma | Recurrent Prostate Adenocarcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

A Study of miRNA 371 in Patients With Germ Cell Tumors

Seminoma | Germ Cell Tumor | Metachronous Malignant Neoplasm | Stage I Testicular Cancer AJCC v8 | Stage IA Testicular Cancer AJCC v8 | Stage IB Testicular Cancer AJCC v8 | Stage IS Testicular Cancer AJCC v8

Canada, United States, Guam
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers

Unresectable Extrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Stage IIIA Gallbladder Cancer AJCC v7 | Stage IIIB Gallbladder Cancer AJCC v7 | Stage IVA Gallbladder Cancer AJCC v7 | Stage IVB Gallbladder Cancer AJCC v7 | Stage III Intrahepatic Cholangiocarcinoma AJCC v7 | Stage... and other conditions

United States
University of Washington
Blaze Bioscience Inc.

Recruiting

A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

Stage III Lip and Oral Cavity Cancer AJCC v8 | Oral Cavity Squamous Cell Carcinoma | Stage I Lip and Oral Cavity Cancer AJCC v8 | Stage II Lip and Oral Cavity Cancer AJCC v8 | Stage IVA Lip and Oral Cavity Cancer AJCC v8

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Recruiting

Prevention of Frailty With Fisetin and Exercise (PROFFi) in Breast Cancer Survivors (PROFFi)

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Early Stage Breast Carcinoma | Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8

United States
National Cancer Institute (NCI)

Completed

Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer

Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB... and other conditions

United States
Mayo Clinic

Recruiting

Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage 0 Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Metastatic Clear Cell Renal Cell Carcinoma | Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Urothelial Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Recurrent Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Stage III Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage... and other conditions

United States
National Cancer Institute (NCI)

Withdrawn

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Anatomic Stage IV Breast Cancer AJCC v8 | Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Metastatic Pancreatic Carcinoma | Refractory Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer... and other conditions

United States
Mamta Parikh
National Cancer Institute (NCI)

Recruiting

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Advanced Prostate Adenocarcinoma

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Lymph Nodes | Metastatic Malignant Neoplasm in the Liver | Metastatic Breast Carcinoma | Metastatic Malignant Neoplasm in the Lung and other conditions

United States, Canada, Saudi Arabia, Korea, Republic of
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Not yet recruiting

Remotely Delivered, Culturally Tailored Weight Loss Interventions Among Latina Breast Cancer Survivors

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Recruiting

Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)

Peritoneal Carcinomatosis | Digestive System Neoplasm | Liver and Intrahepatic Bile Duct Carcinoma | Appendix Carcinoma by AJCC V8 Stage | Colorectal Carcinoma by AJCC V8 Stage | Esophageal Carcinoma by AJCC V8 Stage | Gastric Carcinoma by AJCC V8 Stage

United States
M.D. Anderson Cancer Center

Recruiting

Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Resectable Hepatocellular Carcinoma | Stage I Hepatocellular Carcinoma AJCC v8 | Stage IA Hepatocellular Carcinoma AJCC v8

United States
National Cancer Institute (NCI)

Terminated

Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer

Metastatic Rectal Adenocarcinoma | Rectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Stage IV Rectal Cancer AJCC v7 | Stage IVA Rectal Cancer AJCC v7 | Stage IVB Rectal Cancer AJCC v7 | Locally...

United States
National Cancer Institute (NCI)

Withdrawn

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

Urothelial Carcinoma | Renal Pelvis and Ureter Urothelial Carcinoma | Bladder Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage IVA Bladder Cancer AJCC v8 | Bladder Urothelial Carcinoma | Muscle Invasive Bladder Carcinoma | Stage II Bladder Cancer AJCC v8

Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

Stage III Colon Cancer AJCC v8 | Colon Adenocarcinoma | Microsatellite Stable Colon Carcinoma | Stage IIB Colon Cancer AJCC v8 | Stage IIC Colon Cancer AJCC v8

United States
Rahul Aggarwal
Merck Sharp & Dohme LLC; U.S. Army Medical Research and Development Command; Zenith...

Recruiting

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Metastatic Prostate Small Cell Carcinoma

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Prostate Small Cell Neuroendocrine Carcinoma | Castration-Sensitive Prostate Carcinoma

United States
University of Washington
National Cancer Institute (NCI)

Terminated

IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery

Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIB Ovarian Cancer | Stage IIIB Primary Peritoneal Cancer | Stage IIIC Fallopian Tube Cancer | Stage IIIC Ovarian Cancer | Stage IIIC Primary Peritoneal Cancer and other conditions

United States
Thomas Jefferson University

Not yet recruiting

Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation

Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage IIA Fallopian Tube Cancer | Stage... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

Metastatic Squamous Cell Carcinoma of the Hypopharynx | Metastatic Squamous Cell Carcinoma of the Larynx | Metastatic Squamous Cell Carcinoma of the Oral Cavity | Metastatic Squamous Cell Carcinoma of the Oropharynx | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Recruiting

Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Sarcoma | Lymphoma | Leukemia | Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Clinical Stage III Cutaneous Melanoma AJCC v8 | Thyroid Gland Carcinoma | Clinical... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer

Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer AJCC v7 | Solid Neoplasm

United States, Canada
Thomas Jefferson University
Prostate Cancer Foundation

Active, not recruiting

Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study

Biochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally Advanced Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Locally Advanced Breast Carcinoma | Early Stage Breast Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma

United States

Clinical Trials on Stage IVA Primary Peritoneal Cancer AJCC v8

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations